Answers are grounded in this paper and cite their sources.
Cholecystokinin (CCK) is a peptide initially thought to be solely responsible for gall bladder function. It is now known to be found in both the alimentary tract and central nervous system. CCK has an anti-opioid analgesic effect, its levels are increased by exogenous opioid administration and neural injury. Antagonism of elevated levels is associated with enhanced antinociception. CCK antagonists have also been shown to curtail antinociceptive tolerance in animal models and even to reverse established tolerance.Evidence now exists from human studies of a pro-analgesic effect of the CCK antagonist proglumide in acute, chronic and experimental pain models. Further studies suggest that in humans the CCK A antagonists may be more efficacious than the B antagonists. Further work is needed to define the effect of CCK antagonists in human pain and to define the effect of the CCK antagonists on analgesic tolerance.
No takes yet. Share an insight, caveat, or question.
Gary McCleane (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: